CoCliP-BJI study: cost avoidance of clinical pharmacist-led interventions in patients with bone and joint infections.
Langue
EN
Article de revue
Ce document a été publié dans
Infectious Diseases Now. 2025-05-28p. 105104
Résumé en anglais
Patients with bone and joint infections (BJI) are part of a complex care pathway. This study aimed to evaluate the economic impact of clinical pharmacist-led interventions in the management of BJI patients. We performed a ...Lire la suite >
Patients with bone and joint infections (BJI) are part of a complex care pathway. This study aimed to evaluate the economic impact of clinical pharmacist-led interventions in the management of BJI patients. We performed a retrospective study documenting all pharmacist-led interventions (PI). Their impact was assessed using the clinical economic and organizational scale (CLEO SFPC). The probability of adverse drug events (ADE) in the absence of PI was assessed by a panel of three experts. Cost avoidance was calculated for PIs with major clinical impact using a cost of €5,331 per event, multiplied by the probability of ADE occurrence. A total of 41 PIs had a major clinical impact. Cost avoidance associated with the intervention of a pharmacist was estimated at €83,750.01 during the study. The implementation of pharmacist-led interventions in the management of patients with BJI helps avoid preventable healthcare costs.< Réduire
Mots clés en anglais
Adverse events; Antibiotics; Bone and joint infection; Clinical pharmacy; Medication safety.
Unités de recherche